FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983094092> ?p ?o ?g. }

• W1983094092 endingPage "543" @default.
• W1983094092 startingPage "534" @default.
• W1983094092 abstract "Some men receiving α-blocker therapy for lower urinary tract symptoms report persistent storage symptoms suggestive of overactive bladder (OAB). To evaluate the efficacy of tolterodine extended release (ER) in men on α-blocker therapy. This double-blind trial included men aged ≥40 yr with frequency, urgency, and at least moderate problems reported on the Patient Perception of Bladder Condition (PPBC), despite being on a stable dose of α-blocker for ≥1 mo. Subjects were randomized to tolterodine ER 4 mg per day or placebo for 12 wk while continuing their prescribed α-blocker therapy. At baseline and week 12, subjects completed the PPBC, International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire (OAB-q), and 5-d bladder diaries using the five-point Urinary Sensation Scale (USS). Frequency–urgency sum was defined as the sum of USS ratings for all micturitions. PPBC improvement from baseline to week 12 was reported by 63.6% and 61.6% of subjects receiving tolterodine ER plus α-blocker and placebo plus α-blocker, respectively; this treatment difference, which was the primary end point, was not statistically significant (p > 0.6699). At week 12, subjects receiving tolterodine ER plus α-blocker had significantly greater improvements versus placebo plus α-blocker in 24-h micturitions (−1.8 vs −1.2; p = 0.0079) and daytime micturitions (−1.3 vs −0.8; p = 0.0123); 24-h urgency episodes (−2.9 vs −1.8; p = 0.0010), daytime urgency episodes (−2.2 vs −1.4; p = 0.0017), and nocturnal urgency episodes (−0.5 vs −0.3; p = 0.0378); frequency–urgency sum (−7.8 vs −5.1; p = 0.0065); IPSS storage subscale (−2.6 vs −2.1; p = 0.0370); and OAB-q symptom bother scale (−17.9 vs −14.4; p = 0.0086) and coping domain (15.4 vs 12.4; p = 0.0491). Acute urinary retention requiring catheterization occurred in <1% of either group. There were no clinically meaningful changes in postvoid residual volume or maximum urinary flow rate. Men with bothersome OAB symptoms despite continued α-blocker therapy showed significantly greater improvements in diary variables, IPSS Storage scores, and symptom bother when receiving additional tolterodine ER versus placebo plus α-blocker." @default.
• W1983094092 created "2016-06-24" @default.
• W1983094092 creator A5001479798 @default.
• W1983094092 creator A5057019905 @default.
• W1983094092 creator A5080266362 @default.
• W1983094092 creator A5085416965 @default.
• W1983094092 creator A5091477558 @default.
• W1983094092 creator A5068093441 @default.
• W1983094092 date "2009-09-01" @default.
• W1983094092 modified "2023-10-14" @default.
• W1983094092 title "Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With α-Blockers" @default.
• W1983094092 cites W1514921595 @default.
• W1983094092 cites W1590256680 @default.
• W1983094092 cites W1967312126 @default.
• W1983094092 cites W1967347194 @default.
• W1983094092 cites W1969218478 @default.
• W1983094092 cites W1972275101 @default.
• W1983094092 cites W1987858646 @default.
• W1983094092 cites W2009593049 @default.
• W1983094092 cites W2009972129 @default.
• W1983094092 cites W2018142772 @default.
• W1983094092 cites W2020443535 @default.
• W1983094092 cites W2022805390 @default.
• W1983094092 cites W2028950772 @default.
• W1983094092 cites W2045828646 @default.
• W1983094092 cites W2055614074 @default.
• W1983094092 cites W2065814656 @default.
• W1983094092 cites W2067889220 @default.
• W1983094092 cites W2068543068 @default.
• W1983094092 cites W2078997630 @default.
• W1983094092 cites W2088552272 @default.
• W1983094092 cites W2131173377 @default.
• W1983094092 cites W2134121470 @default.
• W1983094092 cites W2134928141 @default.
• W1983094092 cites W2136535014 @default.
• W1983094092 cites W2154278482 @default.
• W1983094092 cites W2155381616 @default.
• W1983094092 cites W2163974078 @default.
• W1983094092 cites W2171846085 @default.
• W1983094092 cites W4249655375 @default.
• W1983094092 cites W4294545090 @default.
• W1983094092 doi "https://doi.org/10.1016/j.eururo.2008.11.026" @default.
• W1983094092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19070418" @default.
• W1983094092 hasPublicationYear "2009" @default.
• W1983094092 type Work @default.
• W1983094092 sameAs 1983094092 @default.
• W1983094092 citedByCount "162" @default.
• W1983094092 countsByYear W19830940922012 @default.
• W1983094092 countsByYear W19830940922013 @default.
• W1983094092 countsByYear W19830940922014 @default.
• W1983094092 countsByYear W19830940922015 @default.
• W1983094092 countsByYear W19830940922016 @default.
• W1983094092 countsByYear W19830940922017 @default.
• W1983094092 countsByYear W19830940922018 @default.
• W1983094092 countsByYear W19830940922019 @default.
• W1983094092 countsByYear W19830940922020 @default.
• W1983094092 countsByYear W19830940922021 @default.
• W1983094092 countsByYear W19830940922022 @default.
• W1983094092 countsByYear W19830940922023 @default.
• W1983094092 crossrefType "journal-article" @default.
• W1983094092 hasAuthorship W1983094092A5001479798 @default.
• W1983094092 hasAuthorship W1983094092A5057019905 @default.
• W1983094092 hasAuthorship W1983094092A5068093441 @default.
• W1983094092 hasAuthorship W1983094092A5080266362 @default.
• W1983094092 hasAuthorship W1983094092A5085416965 @default.
• W1983094092 hasAuthorship W1983094092A5091477558 @default.
• W1983094092 hasConcept C121608353 @default.
• W1983094092 hasConcept C126322002 @default.
• W1983094092 hasConcept C126894567 @default.
• W1983094092 hasConcept C142724271 @default.
• W1983094092 hasConcept C168563851 @default.
• W1983094092 hasConcept C203092338 @default.
• W1983094092 hasConcept C204787440 @default.
• W1983094092 hasConcept C27081682 @default.
• W1983094092 hasConcept C2776235491 @default.
• W1983094092 hasConcept C2776547966 @default.
• W1983094092 hasConcept C2778531004 @default.
• W1983094092 hasConcept C2778941218 @default.
• W1983094092 hasConcept C2779478474 @default.
• W1983094092 hasConcept C2781020410 @default.
• W1983094092 hasConcept C71924100 @default.
• W1983094092 hasConcept C77411442 @default.
• W1983094092 hasConceptScore W1983094092C121608353 @default.
• W1983094092 hasConceptScore W1983094092C126322002 @default.
• W1983094092 hasConceptScore W1983094092C126894567 @default.
• W1983094092 hasConceptScore W1983094092C142724271 @default.
• W1983094092 hasConceptScore W1983094092C168563851 @default.
• W1983094092 hasConceptScore W1983094092C203092338 @default.
• W1983094092 hasConceptScore W1983094092C204787440 @default.
• W1983094092 hasConceptScore W1983094092C27081682 @default.
• W1983094092 hasConceptScore W1983094092C2776235491 @default.
• W1983094092 hasConceptScore W1983094092C2776547966 @default.
• W1983094092 hasConceptScore W1983094092C2778531004 @default.
• W1983094092 hasConceptScore W1983094092C2778941218 @default.
• W1983094092 hasConceptScore W1983094092C2779478474 @default.
• W1983094092 hasConceptScore W1983094092C2781020410 @default.
• W1983094092 hasConceptScore W1983094092C71924100 @default.
• W1983094092 hasConceptScore W1983094092C77411442 @default.

• next